pharma · MASH · MASLD · SGMT
Sagimet Biosciences
Sagimet Biosciences clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 155 Bovet Rd, Suite 303, San Mateo, California 94402, US
- Employees
- 27
- Programs
- 12
- Drugs
- 4
- Patents
- 1
Sagimet Biosciences projects
4 ClinicalTrials.gov programs sponsored by Sagimet Biosciences.
Sagimet Biosciences has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
3-V Bioscience-2640
Sagimet Biosciences
Metabolic Syndrome
1 trial -
TVB-2640
Sagimet Biosciences
KRAS Gene Mutation
1 trial -
TVB-2640
Sagimet Biosciences
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
1 trial -
TVB-2640 25 mg (US)
Sagimet Biosciences
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
1 trial
Frequently asked questions
How many clinical projects does Sagimet Biosciences have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.